14.32
Rxsight Inc stock is traded at $14.32, with a volume of 681.40K.
It is up +0.85% in the last 24 hours and down -42.35% over the past month.
RxSight Inc is a commercial-stage medical technology company dedicated towards improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The company operates and manages its business in one reportable segment, the research and development, manufacture and sale of light adjustable lenses and related capital equipment.
See More
Previous Close:
$14.20
Open:
$14.39
24h Volume:
681.40K
Relative Volume:
0.91
Market Cap:
$591.97M
Revenue:
$128.29M
Net Income/Loss:
$-30.69M
P/E Ratio:
-17.46
EPS:
-0.82
Net Cash Flow:
$-27.17M
1W Performance:
-2.05%
1M Performance:
-42.35%
6M Performance:
-71.53%
1Y Performance:
-72.64%
Rxsight Inc Stock (RXST) Company Profile
Name
Rxsight Inc
Sector
Industry
Phone
949-521-7822
Address
100 COLUMBIA STREET, ALISO VIEJO
Compare RXST with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
RXST
Rxsight Inc
|
14.32 | 591.97M | 128.29M | -30.69M | -27.17M | -0.82 |
![]()
ABT
Abbott Laboratories
|
131.73 | 218.91B | 41.95B | 13.40B | 6.35B | 7.65 |
![]()
BSX
Boston Scientific Corp
|
95.05 | 139.37B | 16.75B | 1.85B | 2.37B | 1.25 |
![]()
SYK
Stryker Corp
|
348.12 | 134.90B | 22.60B | 2.99B | 3.49B | 7.76 |
![]()
MDT
Medtronic Plc
|
83.37 | 106.90B | 33.20B | 4.26B | 5.47B | 3.29 |
![]()
EW
Edwards Lifesciences Corp
|
70.60 | 41.45B | 5.72B | 4.17B | 259.90M | 6.97 |
Rxsight Inc Stock (RXST) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Apr-15-25 | Initiated | Piper Sandler | Neutral |
Apr-09-25 | Downgrade | UBS | Buy → Neutral |
Apr-04-25 | Downgrade | JP Morgan | Overweight → Underweight |
Apr-03-25 | Downgrade | BofA Securities | Buy → Underperform |
Dec-20-24 | Downgrade | Stifel | Buy → Hold |
Dec-11-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
Dec-06-24 | Initiated | UBS | Buy |
Oct-29-24 | Initiated | Jefferies | Buy |
Aug-20-24 | Reiterated | Needham | Buy |
Aug-06-24 | Reiterated | Needham | Buy |
May-07-24 | Reiterated | BTIG Research | Buy |
Dec-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
Dec-12-23 | Initiated | Stifel | Buy |
Dec-04-23 | Initiated | Morgan Stanley | Overweight |
Apr-13-23 | Initiated | Oppenheimer | Outperform |
Dec-12-22 | Downgrade | Wells Fargo | Overweight → Equal Weight |
Apr-08-22 | Initiated | Needham | Buy |
View All
Rxsight Inc Stock (RXST) Latest News
LPL Financial LLC Boosts Holdings in RxSight, Inc. (NASDAQ:RXST) - Defense World
Geode Capital Management LLC Has $28.57 Million Stock Position in RxSight, Inc. (NASDAQ:RXST) - Defense World
Piper Sandler Initiates Coverage of RxSight (RXST) with Neutral Recommendation - Nasdaq
This Aurora Innovation Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Tuesday - Benzinga
Piper Sandler Initiates RxSight at Neutral With $18 Price Target - marketscreener.com
Piper Sandler Begins Coverage of RxSight (RXST) with Neutral Rat - GuruFocus
Piper Sandler sets RxSight stock target at $18, stays neutral By Investing.com - Investing.com South Africa
Piper Sandler sets RxSight stock target at $18, stays neutral - Investing.com
Piper Sandler Starts RxSight Inc. (RXST) at Neutral - StreetInsider
RxSight price target lowered to $17 from $22 at Wells Fargo - MSN
RxSight plunges after guidance cut; BofA downgrades - MSN
RxSight stock plunges to 52-week low at $14.24 amid market challenges By Investing.com - Investing.com South Africa
RxSight stock plunges to 52-week low at $14.24 amid market challenges - Investing.com
UBS cuts RxSight stock rating to neutral, slashes price target to $16 By Investing.com - Investing.com South Africa
RxSight downgraded at UBS after Q1 miss and guidance cut - MSN
RxSight stock downgraded at UBS on guidance cut (RXST:NASDAQ) - Seeking Alpha
Needham Cuts Price Target on RxSight to $22 From $43, Keeps Buy Rating - MarketScreener
UBS Downgrades RxSight to Neutral From Buy, Cuts Price Target to $16 From $45 - MarketScreener
UBS cuts RxSight stock rating to neutral, slashes price target to $16 - Investing.com Australia
UBS Downgrades RxSight Inc. (RXST) to Neutral - StreetInsider
RxSight at Needham Conference: Strategic Adjustments Amid Market Challenges By Investing.com - Investing.com Canada
Analysts Are Neutral on Top Healthcare Stocks: RxSight (RXST), Johnson & Johnson (JNJ) - The Globe and Mail
Needham & Company LLC Reiterates “Buy” Rating for RxSight (NASDAQ:RXST) - Defense World
Rxsight adjusts 2025 revenue guidance to $160M-$175M amid premium IOL market challenges - MSN
Midday Stock Roundup: Masimo, Virgin Galactic an Others Take Dives - Orange County Business Journal
JP Morgan downgrades RxSight on market, competitive pressures - Investing.com
JPMorgan Downgrades RxSight to Underweight From Overweight, Adjusts Price Target to $17 From $40 - MarketScreener
Deep Dive Into RxSight Stock: Analyst Perspectives (12 Ratings) - Benzinga
RxSight’s preliminary Q1 2025 revenue expected to increase 28% - Medical Buyer
American Express, Rxsight, Vertiv Holdings - TradingView
RxSight Inc (RXST) Q1 2025 Earnings Call Highlights: Strong Year-Over-Year Growth Amid Revised ... By GuruFocus - Investing.com Canada
JPMorgan Double Downgrades RxSight Inc. (RXST) to Underweight - StreetInsider
RxSight: Navigating Market Headwinds Amid Intensifying Competition (Downgrade) - Seeking Alpha
JPMorgan cuts RxSight stock rating, slashes price target to $17 By Investing.com - Investing.com South Africa
JPMorgan cuts RxSight stock rating, slashes price target to $17 - Investing.com
RxSight stock plunges to 52-week low at $15.84 amid market challenges By Investing.com - Investing.com South Africa
RxSight stock plunges to 52-week low at $15.84 amid market challenges - Investing.com India
RxSight downgraded to Underweight from Overweight at JPMorgan - TipRanks
Earnings call transcript: RxSight Q1 2025 sees revenue growth, stock dips By Investing.com - Investing.com South Africa
RxSight Analyst Flags Growth Slowdown As Revised Outlook Misses Expectations - Benzinga
Biotech Shake-Up: Aldeyra Therapeutics & Others Feel The Heat - Finimize
RxSight plunges after guidance cut - MSN
RxSight Plunges 44% After Slashing 2025 Guidance; Bank of America Downgrades Stock - Yahoo Finance
RxSight Plunges 44% After Slashing 2025 Guidance; Bank of Americ - GuruFocus
BTIG cuts RxSight stock price target to $28 from $44 By Investing.com - Investing.com Australia
RxSight stock tumbles on lowered 2025 guidance By Investing.com - Investing.com Canada
RxSight (RXST) Shares Plummet After Revenue Forecast Cut - GuruFocus
RxSight stock tumbles on lowered 2025 guidance - Investing.com
Earnings call transcript: RxSight Q1 2025 sees revenue growth, stock dips - Investing.com Canada
BTIG cuts RxSight stock price target to $28 from $44 - Investing.com
RxSight Q1 Revenue Miss, Guidance Cut Raise Growth Concerns, BofA Says - MarketScreener
Rxsight Inc Stock (RXST) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):